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costs were used. Price for sofosbuvir-ledipasvir was the price used in the early access 
program in France. Results: The incremental cost-effectiveness ratio for patient 
treated at F2F3 ranged from 3 000 € / QALY to 20 000 € / QALY for 8 and 12 weeks treat-
ment duration. The sensitivity analyses carried out confirmed the robustness of this 
result. ConClusions: Sofosbuvir-ledipasvir association is a cost-effective treatment 
option for patients with hepatitis C in most clinical contexts.
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objeCtives: The prevalence of carbapenem-resistant Enterobacteriaceae(CRE) has 
been increasing and proactive surveillance is highly recommended. Patients in inten-
sive care unit (ICU) are particularly prone to CRE acquisition due to multiple risk 
factors. The objective of this study was to examine the potential cost and clinical 
outcomes of active CRE surveillance upon ICU admission from the perspective of 
healthcare providers in Hong Kong. Methods: A Markov model was designed to 
compare the outcomes of active CRE surveillance versus no active surveillance in 
patients admitted to an ICU in Hong Kong. CRE-associated direct medical cost and 
CRE-associated quality-adjusted life years (QALYs) loss were simulated based on the 
model inputs derived from the literature. Sensitivity analyses were conducted to 
evaluate the robustness of the results. Results: In the base-case analysis, active sur-
veillance group showed less QALYs loss (0.3335 vs 0.3827) with higher CRE-associated 
cost (HKD9,825 vs HKD9,800) (USD1= HKD7.8) than control group. The incremental 
cost-effectiveness ratio (ICER) of active surveillance was HKD 500 per QALY saved 
compared to control group. Sensitivity analysis found base-case results robust to 
variation of all model inputs. In 10,000 Monte Carlo simulations, active surveillance 
group was less costly by HKD1,064 per patient (95%CI HKD1,025-1,103; p< 0.001) and 
lower mean QALYs loss by 0.430 (95% CI, 0.422-0.438; p < 0.001) when compared with 
control group. ICERs per QALY saved by the active surveillance group were less than 
the gross domestic product per capita in Hong Kong (HKD330,113) in 99.98% of the 
simulations. ConClusions: Active CRE surveillance upon ICU admission appears to 
be a cost-effective strategy from the perspective of healthcare providers in Hong Kong.
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objeCtives: Sofosbuvir (SOF), a new pan-genotypic inhibitor of the hepatitis C 
virus (HCV), has been approved for use in chronic hepatitis C (CHC) patients, 
having shown unprecedented sustained virologic response (SVR) rates and tol-
erability profile. More recently, the combination of SOF and ledipasvir (LDV) – a 
new HCV inhibitor with potent antiviral activity – has resulted in higher rates of 
SVR, especially in genotype-1 HCV. The objective of this analysis was to assess 
the cost-effectiveness of LDV/SOF fixed-dose combination for the treatment of 
HCV genotype-1 in Portugal. Methods: Cost and effectiveness were based on a 
CHC natural history evolution Markov-type model accounting for the presence 
of cirrhosis and previous treatment experience for genotype-1. The model incor-
porated 5 Metavir score states, 2 SVR states (with and without cirrhosis) and 3 
advanced liver disease states. Results are expressed in incremental costs per life 
year (LY) and quality-adjusted life year (QALY). The choice of comparators was 
based on identical therapeutic indication and financing by the Portuguese National 
Healthcare System (except for SOF which is currently seen as the standard of 
care). Results: Overall LDV/SOF is expected to result in increments between 0.21 
and 6.80 LY (0.26 and 5.80 QALY) depending on the clinical subgroup and compara-
tor, with costs ranging from -56,981€ savings and 23,288€ increment. Incremental 
cost-effectiveness ratios (ICER) varied between LDV/SOF dominance and a maxi-
mum of 10,563€ /LY (9,098€ /QALY). In the comparison against SOF+PegIFN+RBV or 
SOF+RBV, LDV/SOF was shown to be dominant, while versus boceprevir regimens 
ICER varied between 1,896€ /LY (2,597€ /QALY) (experimented cirrhotic) and 10,563€ /
LY (9,098€ /QALY) (experimented non-cirrhotic). When LDV/SOF was compared 
against PegIFN+RBV, the ICER variation was 3,828€ /LY (5,396€ /QALY) (naïve cir-
rhotic) to 8,042€ /LY (6,776€ /QALY) (experimented non-cirrhotic). ConClusions: 
Ledipasvir/sofosbuvir is expected to represent good value for money including 
cost-saving scenarios in the treatment of CHC genotype-1 in Portugal, irrespective 
of the clinical subgroup or comparator.
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objeCtives: Rectal culture-guided antibiotic prophylaxis is an effective strategy 
in preventing post-TRUSBx infections. This study aimed to examine the cost-effec-
tiveness of pre-biopsy rectal swab culture-guided antibiotic prophylaxis in patients 
undergoing TRUSBx from the societal perspective in Hong Kong. Methods: A deci-
sion tree model was designed to compare clinical outcomes and cost of TRUSBx with 
rectal culture-guided versus empirical antibiotic prophylaxis in a hypothetical cohort 
caspofungin. The cost of achieving one more patient successfully treated with anid-
ulafungin, caspofungin, and micafungin compared to fluconazole was € 17,199, € 
23,962, and € 27,339, respectively. The result remained stable despite modification 
of the duration of the first-line and second-line treatments, as well as most of the 
dosing regimens. The probabilistic analysis also remained stable. ConClusions: 
According to the model, anidulafungin produced savings and was the dominant 
treatment compared with micafungin and caspofungin in non-neutropenic adult 
patients with candidemia and/or invasive candidiasis in ICUs in Spain.
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objeCtives: Rotavirus (RV) infection is a leading cause of severe diarrhoea among 
young children in Switzerland and it is associated with a significant financial 
burden. Two RV vaccines are marketed globally, but only RIX4414 is licensed in 
Switzerland. This study aims to evaluate the cost-effectiveness of RV vaccination 
with RIX4414 among children less than 5 years of age in Switzerland. Methods: A 
previously published age-compartmental Markov cohort model with monthly cycles 
was used to evaluate the RV events and the associated health outcomes and costs 
over the first 5 years of a new-born cohort. It compared the RV burden in a cohort of 
84,823 new-borns with or without RIX4414. Transition probabilities, vaccine efficacy, 
Quality-Adjusted-Life-Years (QALY), Swiss specific incidence and costs data were 
obtained from literature or official reports. Retail vaccine price of CHF61.60 per 
dose was used. Incremental cost-effectiveness ratio (ICER) was calculated under 
a payer’s perspective. Extensive sensitivity analyses were also performed to test 
the robustness of the results. Results: The vaccination programme with RIX4414 
at 90% coverage rate would prevent 1,411 hospitalisation (88%), 145 nosocomial 
infections (63%), 3,914 emergency room visits (88%), 13,006 medical visits (87%) and 
27,861 (70%) RV events. From a payer’s perspective, the vaccine cost completely offset 
the direct RV medical cost and vaccination may offer 39 extra QALYs. Sensitivity 
analyses showed that the frequency of medical visits, of RV events and the cost of 
hospitalisation were the key drivers influencing the results. ConClusions: RV 
vaccination programme with RIX4414 could reduce substantially the number of RV 
cases. The vaccine cost offsets the total direct medical costs.
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objeCtives: In the European context, the nonavalent HPV vaccine 
(6/11/16/18/31/33/45/52/58) expands the spectrum of prevention from 75% to 89% 
of HPV-positive cancer cases and from 47% to 82% of precancerous lesions in the cer-
vix, vulva, vagina and anus. This analysis aims to estimate the public health impact 
and the incremental cost-effectiveness of a universal (girls and boys) vaccination 
program with a nonavalent HPV vaccine as compared to the current universal vacci-
nation program with a quadrivalent HPV vaccine (6/11/16/18), in Austria. Methods: 
A dynamic transmission model including a wide range of health and cost out-
comes related to cervical, anal, vulvar, vaginal diseases and genital warts was 
calibrated to Austrian epidemiological data. The clinical impact due to the 5 new 
types was included for cervical diseases only, producing conservative outcomes. In 
the base case, a two-dose schedule, lifelong vaccine type-specific protection and 
a vaccination coverage rate of 60% and 40% for girls and boys respectively for the 
9-year old cohorts were assumed. A threshold of € 30,000/QALY-gained was consid-
ered. Results: Universal vaccination with the nonavalent vaccine was shown to 
be having the potential to reduce the incidence of HPV16/18/31/33/45/52/58 -related 
cervical cancer by 92% and the related CIN2/3 by 96% after 100 years, relative to 75% 
and 76% with the quadrivalent vaccine respectively. Furthermore, the nonavalent 
vaccine was projected to prevent an additional of 8,281 cases of CIN1, 14,893 cases 
of CIN2/3 and 2,544 cases of cervical cancer, over 100 years. Finally, the base case 
analysis resulted into an ICER of approximately € 16,441. ConClusions: The find-
ings of the analysis indicate that universal vaccination with a nonavalent vaccine 
in Austria is estimated to be cost-effective when compared to the quadrivalent 
vaccine across a range of sensitivity analyses and, further reduce the public health 
burden of HPV-related cancers and diseases.
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objeCtives: In France, 190,306 patients were suffering from chronic hepatitis C in 
2012. These patients have a decreased life expectancy and are susceptible to complica-
tions associated with chronic hepatitis. The association of Ledipasvir and Sofosbuvir, 
an interferon-free treatment, has demonstrated in several phase III trials sustained 
viral response (SVR) rates close to a 100% for genotype 1 (G1) and 4 (G4) patients in 
8 to 12 weeks. The objective of this study was to compare the cost-effectiveness of 
using this association in the treatment of chronic HCV infection in multiple clinical 
context including past treatment (naïve or experience), coinfection, cirrhosis and 
stage at treatment initiation. Methods: A Markov model was used to assess the cost-
effectiveness of sofosbuvir-ledipasvir association compare to every available current 
and upcoming strategy. The model simulated the natural history of HCV infection 
from F0 to F4 taking into account the characteristics of the patients at treatment. To 
be conservative, the model also included fibrosis progression for SVR patients. SVR 
rates for F0 to F4 were based on data from clinical trials. Utilities associated with dif-
ferent stages of disease were based on data from the literature. French direct medical 
